Abstract: |
Levorphanol is a widely used opiate analgesic. Although structurally related to morphine, levorphanol has high affinity for a number of receptor subtypes, including both kappa1, and kappa3. Prior reports had implicated a kappa component of levorphanol-induced antinociception. Evidence is now presented suggesting that levorphanol-induced analgesia is produced by a mixture of mu and kappa3 mechanisms. Levorphanol was a potent analgesic in the tail-flick assay, when given systemically, spinally or supraspinally. Isobolographic analysis of the combined administration of levorphanol, spinally and supraspinally implied synergistic interactions. Naloxonazine reduced levorphanol-induced analgesia, implicating a role for mu1 receptors. The kappa1 antagonist nor-binaltorphimine at a dose which reversed analgesia induced by U50,488H did not antagonize levorphanol-induced analgesia. Additional studies revealed no cross tolerance in either direction, between levorphanol with the kappa1 analgesic U50,488H. Together, these results strongly argue against a role for kappa1, receptors in levorphanol-induced analgesia. However, mice tolerant to the kappa3 analgesic, naloxone benzoylhydrazone (NalBzoH), showed cross tolerance to levorphanol, implying a role of kappa3 mechanisms in levorphanol-induced analgesia. © 1992. |
Keywords: |
controlled study; nonhuman; mouse; animal; mice; pain; animal experiment; dose-response relationship, drug; morphine; analgesics; analgesia; drug tolerance; levorphanol; reaction time; injections, intraventricular; 3,4 dichloro n methyl n [2 (1 pyrrolidinyl)cyclohexyl]benzeneacetamide methanesulfonate; naloxone benzoylhydrazone; kappa opiate receptor; naloxonazine; subcutaneous drug administration; intracerebroventricular drug administration; norbinaltorphimine; male; priority journal; article; receptors, opioid, kappa; support, u.s. gov't, p.h.s.; intrathecal drug administration; kappa receptors
|